厄洛替尼与吉非替尼联合治疗非小细胞肺癌脑转移的效果及不良反应发生情况分析

Analysis of effect and adverse reactions of erlotinib and gefitinib in the treatment of non-small cell lung cancer brain metastases

目的研究厄洛替尼、吉非替尼联合治疗非小细胞肺癌脑转移的效果和不良反应发生情况。方法100例非小细胞肺癌脑转移患者,根据随机抽签分组原则分为观察组及对照组,各50例。观察组采取吉非替尼、厄洛替尼联合治疗,对照组采用厄洛替尼单一治疗。对比两组治疗效果、不良反应发生情况、生活质量、免疫功能指标[免疫球蛋白(Ig)G、IgM、IgA]、肺癌进展和生存时间。结果观察组治疗总有效率80.00%高于对照组的52.00%,差异有统计学意义(P<0.05)。观察组患者不良反应发生率4.00%低于对照组的22.00%,差异有统计学意义(P<0.05)。观察组躯体功能评分(98.34±3.23)分、心理功能评分(96.45±2.33)分、社会功能评分(95.98±2.55)分、物质生活评分(95.97±2.16)分均高于对照组的(74.56±2.45)、(75.09±2.67)、(75.98±2.03)、(74.98±2.81)分,差异有统计学意义(P<0.05)。治疗后,观察组患者IgM(1.59±0.71)g/L、IgG(12.02±1.05)g/L、IgA(2.65±1.04)g/L均高于对照组的(1.12±0.24)、(11.21±1.67)、(2.01±1.33)g/L,差异有统计学意义(P<0.05)。观察组患者肺癌进展时间(7.02±1.02)个月、肺癌生存时间(11.64±1.97)个月长于对照组的(5.28±1.67)、(9.83±1.41)个月,差异有统计学意义(P<0.05)。结论通过对非小细胞肺癌脑转移患者实施厄洛替尼、吉非替尼联合治疗,取得了显著的治疗效果,不仅能降低不良反应发生率,改善患者预后,而且具有较高安全性。

Objective To study the effect and occurrence of adverse reactions of erlotinib and gefitinib in the treatment of non-small cell lung cancer brain metastases.Methods A total of 100 patients with nonsmall cell lung cancer brain metastases were divided into observation group and control group according to random lottery method,with 50 cases in each group.The observation group was treated with erlotinib and gefitinib,and the control group was treated with erlotinib alone.The therapeutic effect,occurrence of adverse reactions,quality of life,immune function indicators[immunoglobulin(Ig)G,IgM,IgA],lung cancer progression time and survival time were compared between the two groups.Results The total effective rate of the observation group was 80.00%,which was higher than 52.00%of the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions of the observation group was 4.00%,which was lower than 22.00%of the control group,and the difference was statistically significant(P<0.05).The physical function score(98.34±3.23)points,psychological function score(96.45±2.33)points,social function score(95.98±2.55)points and material life score(95.97±2.16)points of the observation group were higher than(74.56±2.45),(75.09±2.67),(75.98±2.03)and(74.98±2.81)points of the control group,and the difference was statistically significant(P<0.05).After treatment,the IgM(1.59±0.71)g/L,IgG(12.02±1.05)g/L and IgA(2.65±1.04)g/L of the observation group were higher than(1.12±0.24),(11.21±1.67)and(2.01±1.33)g/L of the control group,and the difference was statistically significant(P<0.05).The lung cancer progression time(7.02±1.02)months and survival time(11.64±1.97)months of the observation group were longer than(5.28±1.67)and(9.83±1.41)months of the control group,and the difference was statistically significant(P<0.05).Conclusion Combination of erlotinib and gefitinib shows remarkable effect on patients with non-small cell lung cancer brain metastases,which can not only reduce occurrence of adverse reactions,improve the prognosis of patients,but also has high safety.